• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to Commission A22-66]
2022     NIHR Health Technology Assessment programme The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for sled prosthesis (knee)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Addendum to Commission A22-63]
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ozanimod (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Benefit assessment according to § 35a SGB V]
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to § 35a SGB V]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pralsetinib (RET fusion-positive NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy) - Addendum to Commission A21-135]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Mammographic surveillance in breast cancer patients aged 50 years or older
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Solriamfetol (obstructive sleep apnoea) - Addendum to Commission A21-129]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Search for guidelines on population-based colorectal cancer screening]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, adjuvant) - Benefit assessment according to § 35a SGB V]
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, advanced) - Benefit assessment according to § 35a SGB V]
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Low-intensity pulsed ultrasound for the treatment of pseudarthrosis]
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ripretinib (gastrointestinal stromal tumour (GIST)) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission "Low-intensity pulsed ultrasound for the treatment of pseudarthrosis"]
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Diroximel fumarate (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection - autologous anti-CD19-transduced CD3+ cells]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. NICE interventional procedures guidance 746
2022     NIHR Health Technology Assessment programme Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Preoperative risk factors: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2022     Canary Health Service [Portable neuromodulation stimulation device to improve gait in multiple sclerosis]
2022     National Institute for Health and Care Excellence (NICE) Ab interno canaloplasty for open-angle glaucoma. NICE interventional procedures guidance 745
2022     NIHR Health Technology Assessment programme Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest (Airways-2)
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulmonary thrombectomy using a disc retriever for pulmonary artery embolism]
2022     National Institute for Health and Care Excellence (NICE) Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. NICE interventional procedures guidance 743
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder. NICE interventional procedures guidance 742
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for heart transplantation]
2022     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. NICE interventional procedures guidance 740
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) YAG laser vitreolysis for symptomatic vitreous floaters. NICE interventional procedures guidance 741
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain. NICE interventional procedures guidance 739
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the final study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Third addendum to Commission A20-61]
2022     National Institute for Health and Care Excellence (NICE) Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. NICE interventional procedures guidance 738
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (enthesitis-associated arthritis) - Benefit assessment according to § 35a SGB V]
2022     National Institute for Health and Care Excellence (NICE) Focal resurfacing implants to treat articular cartilage damage in the knee. NICE interventional procedures guidance 734
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (juvenile psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical neuromuscular stimulation for urinary incontinence. NICE interventional procedures guidance 735
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (oesophageal or gastroesophageal junction carcinoma) - Addendum to Commission A21-144]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, fifth line) - Benefit assessment according to §35a Social Code Book V]
2022     National Institute for Health and Care Excellence (NICE) Superficial venous arterialisation for chronic limb threatening ischaemia. NICE interventional procedures guidance 736
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adolescents - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2022     National Institute for Health and Care Excellence (NICE) Bioresorbable stent implantation to treat coronary artery disease. NICE interventional procedures guidance 732
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: biologic dose escalation - gastroenterology, rheumatology and dermatology]
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a scientific concept for the generation of routine practice data and their analysis for benefit assessments according to §35a Social Code Book (SGB) V in the event of market access for several drugs of one drug class]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]